We found that patients with BL tumors with TP53 mutations and co-occurring HRD-high cluster had much shorter PFS compared with those with either TP53 mutations in the absence of the HRD-high cluster, or patients with the HRD-high cluster in the absence of TP53 mutations (TP53 + HRD-high vs. wild type; HR = 16.3, p = 1.78e−07; q = 5.34e−07; Fig. 2g). This evidence concerns the gene TP53 and Burkitt lymphoma.